NEW YORK ─ NanoDx on Wednesday announced a licensing agreement for use of IBM Research's metal-oxide semi-conductive compatible nanoscale sensors to expand rapid testing for COVID-19, traumatic brain injury, sepsis, and stroke, among other indications.
Southborough, Massachusetts-based NanoDx is developing a point-of-care diagnostics platform that uses nanosensor technology to detect and quantify biomarkers from a small fluid specimen in less than two minutes. Among its diagnostic assays in development, the company is pursuing a US Food and Drug Administration Emergency Use Authorization for a two-minute, point-of-care COVID-19 test.
"As we move forward, our access to IBM's technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost," Sharad Joshi, NanoDx's president and CEO, said in a statement.
Financial and other terms of the agreement were not disclosed.